Your browser is no longer supported. Please, upgrade your browser.
NNVC NanoViricides, Inc. monthly Stock Chart
NNVC [NYSE]
NanoViricides, Inc.
Index- P/E- EPS (ttm)-2.22 Insider Own28.05% Shs Outstand4.54M Perf Week-22.84%
Market Cap11.35M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.75M Perf Month35.14%
Income-8.10M PEG- EPS next Q- Inst Own3.10% Short Float5.25% Perf Quarter-43.26%
Sales- P/S- EPS this Y11.10% Inst Trans-18.05% Short Ratio3.08 Perf Half Y-50.00%
Book/sh2.37 P/B1.05 EPS next Y- ROA-58.60% Target Price- Perf Year-65.28%
Cash/sh0.20 P/C12.61 EPS next 5Y- ROE-70.40% 52W Range1.27 - 13.60 Perf YTD-37.50%
Dividend- P/FCF- EPS past 5Y15.10% ROI- 52W High-81.62% Beta1.19
Dividend %- Quick Ratio0.50 Sales past 5Y- Gross Margin- 52W Low96.65% ATR0.32
Employees17 Current Ratio0.50 Sales Q/Q- Oper. Margin- RSI (14)51.98 Volatility10.23% 11.67%
OptionableNo Debt/Eq0.00 EPS Q/Q23.70% Profit Margin- Rel Volume0.15 Prev Close2.39
ShortableNo LT Debt/Eq0.00 EarningsNov 25 Payout- Avg Volume46.79K Price2.50
Recom- SMA201.35% SMA5011.69% SMA200-43.23% Volume6,980 Change4.60%
Feb-11-15Initiated Midtown Partners Strong Buy $5.30
Dec-03-19 07:30AM  NanoViricides Founder Dr. Diwan Provides $2,000,000 Loan Commitment to the Company ACCESSWIRE -11.16%
Dec-02-19 07:30AM  NanoViricides Has Initiated Required Safety Pharmacology Assessment of Lead Drug Candidate towards IND ACCESSWIRE -5.63%
Nov-19-19 09:00AM  NanoViricides Files Quarterly Report for Period Ending September 30, 2019 - HerpeCide Drug Candidate IND Enabling Studies Update, Progressing Towards Clinical Trials ACCESSWIRE +8.72%
Nov-04-19 07:30AM  NanoViricides Completes Licensing for VZV Field which Includes Shingles Drug Development ACCESSWIRE
Oct-31-19 07:30AM  NanoViricides Initiates Required Dermal Sensitization and Ocular Irritation Testing of Lead Drug Candidate towards IND ACCESSWIRE
Oct-25-19 09:20AM  NanoViricides, Inc., Builds Promising Pipeline Targeting a Multi-Billion Dollar Market for Herpes and Shingles ACCESSWIRE +13.70%
Oct-09-19 07:30AM  NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101 ACCESSWIRE
Oct-03-19 07:30AM  NanoViricides is Creating Nanomedicines to Develop Antiviral Therapies to Combat Shingles and Herpes Viruses Interviewing with Proactive Investors, President & Chairman Anil R. Diwan Outlines the History and Cutting Edge Technology Driving Proprietary Therapies ACCESSWIRE -16.50%
Sep-30-19 07:30AM  NanoViricides, Inc. Files Form S-1 Registration Statement ACCESSWIRE -21.15%
Sep-20-19 11:33AM  What Percentage Of NanoViricides, Inc. (NYSEMKT:NNVC) Shares Do Insiders Own? Simply Wall St. +5.43%
Sep-12-19 09:00AM  NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split PR Newswire -7.04%
Aug-26-19 07:30AM  NanoViricides, Inc. Has Filed its Annual Report, Company Advancing Rapidly Towards First IND PR Newswire
Aug-05-19 07:00AM  NanoViricides Reports Its First Drug Candidate is on Track with GLP Safety/Toxicology Studies toward Human Clinical Trials PR Newswire
Jul-11-19 10:10AM  Does The NanoViricides, Inc. (NYSEMKT:NNVC) Share Price Fall With The Market? Simply Wall St.
Jun-10-19 07:00AM  NanoViricides, Inc. Appoints Dr. Mark Day to its Board of Directors PR Newswire
Jun-03-19 07:00AM  NanoViricides has Received Favorable FDA Comments on Its Pre-IND Application for the Lead Drug Candidate PR Newswire -9.09%
May-20-19 07:00AM  NanoViricides Files Quarterly Report for Period Ending March 31, 2019 - HerpeCide Drug Candidate Pre-IND Application Submitted, Progressing Towards Clinical Trials PR Newswire
Apr-24-19 01:00PM  Some NanoViricides (NYSEMKT:NNVC) Shareholders Have Taken A Painful 92% Share Price Drop Simply Wall St.
Apr-16-19 07:00AM  NanoViricides Submits Pre-IND Briefing Documents to the US FDA PR Newswire
Apr-09-19 09:00AM  NanoViricides Provides Update on Pre-IND Meeting with the US FDA, GLP Safety/Toxicology Studies to Begin Soon, Multiple Kg Scale Drug Production Accomplished at Its Own Facility PR Newswire +7.03%
Mar-26-19 07:00AM  NanoViricides has Requested a Pre-IND Meeting with the US FDA PR Newswire -5.14%
Mar-12-19 07:00AM  NanoViricides Reports Successful Completion of Another Important Safety Study towards an IND PR Newswire
Mar-05-19 07:00AM  NanoViricides Reports Excellent Safety Profile of Its First Drug Candidate in Dermal Treatment Study PR Newswire -11.59%
Feb-27-19 09:48AM  NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering PR Newswire -31.44%
Feb-26-19 07:00AM  NanoViricides Reaches an Agreement on Terms of License for Shingles Virus Drug Development PR Newswire +40.29%
Feb-19-19 07:28AM  NanoViricides: Fiscal 2Q Earnings Snapshot Associated Press +8.97%
07:00AM  NanoViricides Files Quarterly Report for Period Ending December 31, 2018 - HerpeCide Drug Candidate Progressing in IND-Enabling Studies Towards Clinical Trials PR Newswire
Feb-11-19 07:00AM  NanoViricides President Dr. Diwan to Present at the BIO CEO & Investor 2019 Event in New York City Tomorrow Feb 12th at 2:30pm PR Newswire -6.80%
Feb-04-19 07:00AM  NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials PR Newswire +11.11%
Jan-15-19 11:50AM  NNVC: Initiating Coverage Zacks Small Cap Research -7.57%
Jan-02-19 07:00AM  NanoViricides, Inc. CEO Dr. Taraporewala To Present At The Biotech Showcase Investment Conference In San Francisco on January 7, 2019 PR Newswire +12.60%
Nov-26-18 07:35AM  NanoViricides: Fiscal 1Q Earnings Snapshot Associated Press
07:00AM  NanoViricides Files Quarterly Report for Period Ending September 30, 2018 PR Newswire
Nov-13-18 10:35AM  NNVC: NanoViricides: Developing Antiviral Medication Using Nanotechnology Zacks Small Cap Research -14.38%
Oct-29-18 07:00AM  NanoViricides, Inc. Appoints Mr. James Sapirstein to its Board of Directors PR Newswire
Oct-22-18 07:00AM  NanoViricides CEO Dr. Irach Taraporewala Presents a Letter to Shareholders PR Newswire +9.23%
Oct-15-18 07:00AM  NanoViricides Has Filed its Annual Report, Company Reports Strong Progress in Advancement of HerpeCide Program PR Newswire -10.25%
Sep-28-18 07:00AM  NanoViricides Inc. to Present at the MicroCap Conference in New York City on October 1 PR Newswire -9.48%
Sep-26-18 07:22AM  Who Are The Major Shareholders Of NanoViricides Inc (NYSEMKT:NNVC)? Simply Wall St. -8.85%
Sep-05-18 07:00AM  NanoViricides Inc. to Present at 20th Annual Rodman & Renshaw Conference in NYC on Sept 6th PR Newswire -8.58%
Aug-21-18 08:00AM  President and Chairman of the Board of Directors, Anil R. Diwan, Ph.D., of NanoViricides, Inc., Discusses Company Updates with Everett Jolly on Uptick Newswires Stock Day Podcast GlobeNewswire
Aug-07-18 07:00AM  NanoViricides Reports Its Topical Dermal Shingles Candidates Effective in Reducing Pain in Animal Study PR Newswire
Jul-23-18 07:00AM  NanoViricides, Inc. Welcomes Dr. Irach Taraporewala as the New CEO PR Newswire
Jul-12-18 07:00AM  NanoViricides Provides Update on Recent Events PR Newswire
Jun-26-18 07:00AM  Progress of NanoViricides' Shingles Drug Program Presented at the 31st International Conference on Antiviral Research PR Newswire
Jun-19-18 07:20AM  Wired News AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress ACCESSWIRE
May-22-18 07:00AM  NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates PR Newswire
05:02AM  NanoViricides: Fiscal 3Q Earnings Snapshot Associated Press
Apr-09-18 07:00AM  NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today PR Newswire
Mar-19-18 11:12AM  NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin PR Newswire -5.43%
Mar-05-18 06:19PM  Is NanoViricides Incs (NYSEMKT:NNVC) CEO Paid Enough Relative To Peers? Simply Wall St.
Feb-26-18 07:40AM  Blog Exposure - Shire Gets BLA and Priority Review Status from FDA for Lanadelumab for the Prevention of HAE Attacks ACCESSWIRE
Feb-21-18 07:25AM  NanoViricides reports 2Q loss Associated Press
07:00AM  NanoViricides Files Quarterly Report for Period Ending December 31, 2017 PR Newswire
Feb-14-18 02:49PM  How Does NanoViricides Inc (NYSEMKT:NNVC) Affect Your Portfolio Returns? Simply Wall St.
Feb-12-18 08:56AM  Who Are The Largest Shareholders In NanoViricides Inc (NYSEMKT:NNVC)? Simply Wall St.
Dec-06-17 07:00AM  Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates PR Newswire
Nov-20-17 06:34PM  Is NanoViricides Inc (NNVC) A Financially Sound Company? Simply Wall St.
07:00AM  NanoViricides Files Quarterly Report for Period Ending September 30, 2017 PR Newswire
Nov-08-17 05:30PM  NanoViricides Signs Extension of Herpes Virus (HSV) Testing Agreement with University of Wisconsin ACCESSWIRE
Nov-06-17 07:00AM  NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology PR Newswire
Oct-26-17 07:00AM  Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center PR Newswire
Oct-17-17 07:00AM  NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology PR Newswire
Sep-29-17 07:30AM  NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials PR Newswire
Sep-11-17 09:04AM  NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017 PR Newswire
Jul-10-17 07:00AM  NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin PR Newswire
Jun-26-17 09:00AM  NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology PR Newswire
Jun-20-17 07:00AM  NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology PR Newswire
Jun-13-17 07:00AM  NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City PR Newswire
Jun-06-17 05:30PM  NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies PR Newswire
May-16-17 07:58AM  NanoViricides reports 3Q loss Associated Press
07:50AM  NanoViricides Files Quarterly Report for Period Ending 2017-03-31 PR Newswire
Apr-26-17 05:00PM  NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles PR Newswire
Feb-18-17 01:04PM  NANOVIRICIDES, INC. Financials
Feb-16-17 07:00AM  NanoViricides Files Quarterly Report for Period Ending 2016-12-31 PR Newswire
Feb-15-17 05:03AM  NanoViricides reports 2Q loss Associated Press
Feb-14-17 06:02PM  NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report
Feb-13-17 05:33PM  NANOVIRICIDES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secur
07:00AM  NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company PR Newswire
Dec-15-16 04:54PM  NANOVIRICIDES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Dec-05-16 11:43AM  NanoViricides, Inc. :NNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : December 5, 2016
Dec-01-16 07:00AM  NanoViricides Publishes a Letter from the CEO to Shareholders on its Website PR Newswire
Nov-15-16 07:00AM  NanoViricides Files Quarterly Report for Period Ending 2016-09-30 PR Newswire
Nov-14-16 05:04PM  NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report
Nov-07-16 07:00AM  NanoViricides President Dr. Diwan Gave Invited Talks on Regulatory Aspects of Nanomedicines PR Newswire
Oct-31-16 07:00AM  NanoViricides Signs Agreement with SUNY Upstate Medical Center for Testing of Its Drug Candidates for the Treatment of Shingles PR Newswire
Oct-11-16 07:00AM  NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials PR Newswire
Sep-16-16 04:53PM  NANOVIRICIDES, INC. Files SEC form 10-K, Annual Report
Sep-13-16 12:01AM  NanoViricides to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City Today PR Newswire
Aug-25-16 07:00AM  NanoViricides Reports on Senator Murphy's Visit to the Company's Shelton Campus PR Newswire
Jun-20-16 07:00AM  NanoViricides Reports On Progress of Its Drug Candidates against Herpesviruses PR Newswire
Jun-09-16 07:00AM  NanoViricides to Present at the LDMicro Invitational Conference PR Newswire
Jun-08-16 06:04PM  NanoViricides, Inc. :NNVC-US: Earnings Analysis: Q3, 2016 By the Numbers : June 8, 2016
Jun-07-16 07:00AM  NanoViricides to Present at the BIO2016 International Convention - on June 8, 2016, at 11a.m. Pacific Time PR Newswire
May-31-16 07:00AM  NanoViricides Signs Agreement with St. Jude Children's Research Hospital for further Influenza Drug Development PR Newswire
May-26-16 04:05PM  NanoViricides, Inc. To Present at the 5th Annual SeeThruEquity Microcap Investor Conference in New York City on May 31, 2016 Accesswire
May-11-16 07:00AM  NanoViricides Files Quarterly Report for Period Ending 2016-03-31 PR Newswire
May-10-16 04:36PM  NANOVIRICIDES, INC. Files SEC form 10-Q, Quarterly Report
Apr-18-16 07:00AM  NanoViricides, Inc. Recognized as one of the Most Innovative Businesses-2016 by AI Global Media - Acquisitions International PR Newswire
Mar-21-16 07:00AM  NanoViricides, Inc. CEO Dr. Seymour Interview by Small Cap Nation is on YouTube PR Newswire
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.